Seattle Genetics: Good time to buy based on Adcetris label expansion
- Seattle Genetics recently reported halt of its trials for vadastuximab.
- The company awaits some key FDA decisions for expanding the addressable market for Adcetris.
- The stock is attractively valued for medium to long term investment at current price level.
Seattle Genetics (SGEN) is a midsized company with outsized dreams. Those dreams, thus far, were mostly centered around revenues it made from its one big show - Adcetris - in one small market, 2nd line classical Hodgkins lymphoma, and in another even smaller market, 2nd line Systemic anaplastic large cell lymphoma (sALCL), a very rare type of non-Hodgkin lymphoma. The company tried to expand the scope of their ADC (antibody-drug conjugate) platform but there were failures, which, in effect, took it back to that one drug in those two small markets.
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.